ClinicalTrials.gg
WithdrawnNCT03298581Updated Jun 14, 2021

Multiple-Dose Pharmacokinetics and Potential for Adrenal Suppression Following Treatment With Halobetasol Spray in Patients With Plaque Psoriasis

A Phase 2 interventional study of Halobetasol Propionate in Plaque Psoriasis, sponsored by Sun Pharmaceutical Industries Limited. Withdrawn. Open to participants aged 12 Years to 70 Years. Per ClinicalTrials.gov, last updated 2021-06-14.

Sponsored by Sun Pharmaceutical Industries Limited · Phase 2, Interventional, and Treatment

Why this study was withdrawn
Sponsor decision

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Jan 2017, registered Sep 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
12 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 16 studies testing halobetasol in Psoriasis — none open to participants now, 1 under way, none of them phase 3. halobetasol · Psoriasis.

Enrollment
16th of 16
0 · median 151
Started
2017
the only one that year
Phase 2
5 of 16
none open now
Registered
13th of 16
by date
Lead sponsor
1 of 16
Sun Pharmaceutical Industries Limited

Among the 16 studies testing halobetasol in Psoriasis, this one is the 16th largest by enrollment, is the only one that started in 2017, is one of 5 in phase 2, and was the 13th registered.

Psoriasis

2,032 studies on the registry are indexed under Psoriasis; 278 are open to participants now.

Browse Psoriasis studies →

Open to participants now

None of the 16 studies testing halobetasol in Psoriasis is open now. The open studies under Psoriasis, anywhere →

About halobetasol

halobetasol: first FDA approval 1990 (ULTRAVATE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 174 Psoriasis studies recruiting now, 92 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 41 take healthy volunteers.

This study: 12 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies testing halobetasol in Psoriasis as a file.
02

Study summary

This is an open-label, safety study designed to assess the multiple-dose pharmacokinetics and potential for adrenal suppression following topical treatment with halobetasol propionate 0.05% spray applied twice-daily in adult patients with moderate to severe plaque psoriasis. At least 40 eligible patients with plaque psoriasis that satisfy all eligibility criteria will be enrolled into the study

Read the detailed description

This is an open-label, safety study designed to assess the multiple-dose pharmacokinetics and potential for adrenal suppression following topical treatment with halobetasol propionate 0.05% spray applied twice-daily in adult patients with moderate to severe plaque psoriasis. At least 40 eligible patients with plaque psoriasis that satisfy all eligibility criteria will be enrolled into the study. Patients must be overall in good health and should have a current diagnosis of moderate to severe plaque psoriasis with Investigator Global Assessment (IGA) score of at least 3 or 4. Patients will be stratified by age with:

Cohort 1: At least 20 patients 18 years of age and older with ≥ 20% body surface area (BSA) affected Cohort 2: At least 20 patients 12-16 years and 11 months of age with ≥ 10% BSA affected Cohort 2 will initiate enrollment once all enrolled patients in Cohort 1 have completed the study and a safety analysis has been reviewed by the Medical Monitor and approved by the Novum Independent Institutional Review Board (NIIRB). Sites will not begin enrollment of patients in Cohort 2 until the site is notified by email that the safety analysis for Cohort 1 has been reviewed and approved. Confirmation of email receipt will be required from each Investigator before enrollment of Cohort 2 can begin. Each cohort will be enrolled based on the availability of patients. Each cohort will be reviewed for the potential of HPA axis suppression. The Medical Monitor or NIIRB may discontinue the study at any time if safety concerns are found. If 6 or more patients in Cohort 1 experience HPA axis suppression, then enrollment for Cohort 1 will be stopped. Cohort 2 will not be initiated if 6 or more patients enrolled in Cohort 1 experience HPA axis suppression or 30% or more of the final enrolled number of patients in Cohort 1 experience HPA axis suppression. If 6 or more patients in Cohort 2 experience HPA axis suppression, then enrollment for Cohort 2 will be stopped. If the study is stopped at any time, patients currently enrolled will be contacted via phone and instructed to discontinue study product immediately. Patients will be instructed to return for their next scheduled visit for cortisol response testing. Sites will follow up with patients and monitor for HPA axis suppression. All patients will be followed until cortisol levels are normal.

Patients will be instructed to apply topical spray twice daily onto the affected skin areas for 28 days. Patients will be instructed not to rub over the affected area after application of spray Patients will apply the morning dose of the study product in the clinic at each clinic visit and at home during non-clinic visits. A phone call will be made approximately 14 days after the patient has completed dosing to follow-up on any new adverse events that may have occurred

03

Conditions studied

  • Plaque Psoriasis

Browse trials for

04

Who can participate

Ages eligible
12 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males or non-pregnant, non-lactating females:

    • Cohort 1: 18 years of age and older
    • Cohort 2: 12-16 years and 11 months of age (Cohort 2 will not begin enrollment until review and approval of safety information from Cohort 1.)
  2. If female and of , prepared to abstain from sexual intercourse or use a reliable method of during the study (e.g., condom, IUD, oral, transdermal or injected hormonal contraceptives). Female patients using hormonal contraceptives should have been on the same product/dosing regimen for at least 28 days before baseline and should not change this regimen during the study.
  3. Signed form that meets all criteria of current FDA regulations. For a patient considered to be a minor in the state he/she lives and is enrolled, the parent or legal guardian will be required to sign the consent form and the patient will sign an IRB approved "assent to participate" form. Approved informed consent and assent forms specific to each cohort will be required.
  4. Patients with a definite clinical diagnosis of stable plaque psoriasis with:

    • Cohort 1: 18 years of age and older with ≥ 20% BSA affected (excluding the face, scalp, groin, axillae and other intertriginous areas)
    • Cohort 2: 12-16 years and 11 months of age with ≥ 10% BSA affected (excluding the face, scalp, groin, axillae and other intertriginous areas)
  5. Investigator Global Assessment (IGA) score of 3 (Moderate) or 4 (Severe).
  6. Patients in Cohort 2 must weigh a minimum of 24 kg.
  7. Results from a cortisol response test that are considered normal and show no evidence of any abnormal HPA function or adrenal response. Patients must fulfill all of the following stipulations:

    1. Basal (pre-Cortrosyn™ injection) cortisol concentration ≥ 5 mcg/100 mL.
    2. 30-minute post-injection cortisol level is at least 7 mcg/100 mL greater than the basal level (≥ basal value + 7).
    3. Post-stimulation level > 18 mcg/100 mL.

Exclusion criteria

Exclusion Criteria:

  1. Females who are pregnant, nursing, planning to become pregnant during the duration of the study, or if of and sexually active and not prepared to use appropriate methods to avoid pregnancy.
  2. Lacks stable diagnosis of plaque psoriasis or has been diagnosed with mild plaque psoriasis.
  3. IGA score \< 3.
  4. Plaque psoriasis with a BSA involvement \< 20% for Cohort 1 or \< 10% for Cohort 2.
  5. Current diagnosis of types of psoriasis other than stable plaque psoriasis (i.e., erythrodermic, exfolative or pustular psoriasis).
  6. Results from a cortisol response test that show evidence of any abnormal HPA function or adrenal response:

    1. Basal (pre-CortrosynTM injection) cortisol concentration \< 5 mcg/100 mL.
    2. 30-minute post-injection cortisol level is less than 7 mcg/100 mL greater than the basal level (\< basal value + 7).
    3. Post-stimulation level ≤ 18 mcg/100 mL.
  7. Patient has a history of plaque psoriasis that has been unresponsive to topical therapy.
  8. Any condition (i.e., sunburn, atopic or contact dermatitis, etc.) that, in the Investigator's opinion, may interfere with the clinical assessments of the signs and symptoms of plaque psoriasis.
  9. History of prolonged bleeding or a past diagnosis of bleeding disorders and/or history of blood loss exceeding 450 mL (including blood donations) within 1 month before the study.
  10. Patient with poor peripheral venous access.
  11. History of mastectomy or lymphatic insufficiency of the upper limb (patient is eligible if blood can be taken from the arm opposite the site of surgery or condition).
  12. History of allergy or sensitivity to corticosteroids or history of any drug or intolerance that in the opinion of the Investigator, would compromise the safety of the patient or the results of the study.
  13. Patient has a significant history or current evidence of chronic infectious disease, system disorder, Netherton's Syndrome, uncontrolled diabetes, organ disorder or insufficiency, (from medical treatment or disease) or other medical condition (including active or recurrent bacterial, viral or fungal infection or open wounds) that, in the Investigator's opinion, would place the study patient at undue risk by participation in the study or as an unsuitable candidate for the study.
  14. Patients who have a history of or current diagnosis of glaucoma or posterior subcapsular cataracts or any other ocular condition that, in the opinion of the Investigator, would place study patient at undue risk.
  15. Patient is currently receiving or has received any radiation therapy or anti-neoplastic agents within 3 months before baseline.
  16. Use within 4 weeks before baseline of 1) oral or intravenous corticosteroids, 2) UVA/UVB therapy, 3) PUVA (psoralen plus ultraviolet A therapy, 4) prescription strength anti-inflammatory agents, 5) topical tacrolimus or pimecrolimus or 6) any other systemic psoriasis treatment.
  17. Known history of hypothalamic-pituitary-adrenal axis impairment or any other disturbance of the adrenal function (e.g., Cushing or Addison disease).
  18. Use of tanning booths or nonprescription UV light source within 2 weeks before baseline.
  19. Use within 8 weeks before baseline of 1) immunomodulators or immunosuppressive therapies, 2) interferon or 3) systemic retinoids.
  20. Use within 14 days before baseline of 1) systemic antibiotics, 2) calcipotriene or other Vitamin D preparations, or 3) topical retinoids.
  21. Patients who have used topical treatments, prescription or over the counter, including:

    1. Any topical anti-psoriatic therapeutic agents of any kind within the 2 weeks before baseline.
    2. Any topical corticosteroids within the 2 weeks before baseline.
    3. Any antibacterial, medicated and/or astringent washes, soaps, pads or moisturizers within 3 days before baseline.
    4. High strength (20% or above) alpha-hydroxy acid or any kind of peel or other procedures (e.g., laser hair removal) within 30 days before baseline.
    5. Any topical products (i.e., sunscreens, lotions, creams), except for bland emollient (moisturizer) within 24 hours before baseline.
    6. Topical antibiotics in the treatment area within 7 days before baseline.
    7. New regimens of beta blockers.
    8. Lithium preparations within 2 weeks before baseline.
    9. Anti-malarial agents within 2 weeks before baseline.
  22. Patient has been treated within 6 months before baseline with any biological therapies for psoriasis.
  23. Inability to understand the protocol requirements, instructions, and study related restrictions, the nature, scope, and possible consequences of the clinical study.
  24. Unlikely to comply with the protocol requirements, instructions, and study-related restrictions, such as uncooperative attitude, inability to return for follow-up visits, and improbability of completing the clinical study.
  25. Receipt of any drug as part of a research study within 30 days before baseline.
  26. The patient is a member of the study staff or a member of the family of the investigational study staff.
  27. Previous participation in this study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Halobetasol propionate spray 0.05%

    Patients will instructed o apply halobetasol spray twice daily for 14 days and not to rub over the affected area after application of spray.

    Drug: Halobetasol Propionate

Interventions

  • Experimental: Treatment with topical halobetasol spray 0.05% Patients will instructed o apply halobetasol spray twice daily for 28 days and not to rub over the affected area after application of spray.

    Also known as: Topical treatment with Halobetasol spray

06

What researchers measure

Primary outcomes

  1. Change from baseline in the IGA score at Day 28

    Patients will be considered to have shown improvement in disease severity if the IGA score decreases by at least one unit from the baseline score, and will be considered a treatment success if the IGA score is either 0 (clear) or 1 (minimal).

    Time frame: 28 days

Secondary outcomes

  1. Hypothalamic Pituitary Adrenal (HPA) Axis suppression

    Hypothalamic Pituitary Adrenal (HPA) Axis Response to Cosyntropin demonstrating the absence or presence, defined by 30 minute post- CortrosynTM injection level cortisol level of ≤18 mcg/100 mL, at the end of treatment.

    Time frame: 28 days

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2017 to primary completion in Jan 2018, 12 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2017
First posted
Oct 2, 2017
StartActual
Jan 1, 2017
Primary completionActual
Jan 31, 2018
CompletionActual
Jan 31, 2018
Last update
Jun 14, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 14, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03298581
Collaborators
Novum Pharmaceutical Research Services
Responsible party
Sponsor
First posted
Oct 2, 2017
Start date
Jan 1, 2017
Primary completion
Jan 31, 2018
Completion
Jan 31, 2018
Last update
Jun 14, 2021

Study contacts

Rajinder k Jalali, MD
study director · Sun Pharmaceutical Industries Limited

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Halobetasol

Start the discussion